Cambridge Cancer Genomics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

Cambridge Cancer Genomics General Information

Description

Developer of a medical test platform designed to track the response to cancer therapy. The company's platform monitors the proportion of circulating tumor DNA in a patient's blood sample to determine how a patient is responding to therapy, enabling clinicians to monitor treatment response in near real-time, leading to rapid decision-making on the choice of therapy to improve patient quality of life and survival rates.

Contact Information

Website
www.ccg.ai
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 72 Hills Road
  • Cambridge CB2 1LA
  • England, United Kingdom
Primary Industry
Decision/Risk Analysis
Acquirer
Corporate Office
  • 72 Hills Road
  • Cambridge CB2 1LA
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cambridge Cancer Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 23-Jun-2021 Completed Generating Revenue
10. Secondary Transaction - Private Completed Generating Revenue
9. Early Stage VC 03-Jul-2020 Completed Generating Revenue
8. Accelerator/Incubator 30-Jan-2020 Completed Generating Revenue
7. Early Stage VC 18-Dec-2018 Completed Generating Revenue
6. Early Stage VC 01-Nov-2017 Completed Startup
5. Early Stage VC 22-Aug-2017 Completed Startup
4. Accelerator/Incubator 21-Aug-2017 Completed Startup
3. Early Stage VC 01-Aug-2017 Completed Startup
2. Accelerator/Incubator Completed Startup
To view Cambridge Cancer Genomics’s complete valuation and funding history, request access »

Cambridge Cancer Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Cambridge Cancer Genomics’s complete cap table history, request access »

Cambridge Cancer Genomics Patents

Cambridge Cancer Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200185055-A1 Methods and systems for nucleic acid variant detection and analysis Inactive 12-Oct-2018
WO-2020077232-A1 Methods and systems for nucleic acid variant detection and analysis Inactive 12-Oct-2018

Cambridge Cancer Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cambridge Cancer Genomics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
AME Cloud Ventures Venture Capital Minority
Accelerate Cambridge Accelerator/Incubator
Amplify Partners Venture Capital Minority
Comprehensive Blood & Cancer Center Corporation Minority
Endure Capital Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Cambridge Cancer Genomics FAQs

  • When was Cambridge Cancer Genomics founded?

    Cambridge Cancer Genomics was founded in 2016.

  • Where is Cambridge Cancer Genomics headquartered?

    Cambridge Cancer Genomics is headquartered in Cambridge, United Kingdom.

  • What is the size of Cambridge Cancer Genomics?

    Cambridge Cancer Genomics has 7 total employees.

  • What industry is Cambridge Cancer Genomics in?

    Cambridge Cancer Genomics’s primary industry is Decision/Risk Analysis.

  • Is Cambridge Cancer Genomics a private or public company?

    Cambridge Cancer Genomics is a Private company.

  • What is Cambridge Cancer Genomics’s current revenue?

    The current revenue for Cambridge Cancer Genomics is .

  • How much funding has Cambridge Cancer Genomics raised over time?

    Cambridge Cancer Genomics has raised $13.9M.

  • Who are Cambridge Cancer Genomics’s investors?

    AME Cloud Ventures, Accelerate Cambridge, Amplify Partners, Comprehensive Blood & Cancer Center, and Endure Capital are 5 of 16 investors who have invested in Cambridge Cancer Genomics.

  • When was Cambridge Cancer Genomics acquired?

    Cambridge Cancer Genomics was acquired on 23-Jun-2021.

  • Who acquired Cambridge Cancer Genomics?

    Cambridge Cancer Genomics was acquired by Dante Labs.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process